Key result
JCAD promotes endothelial dysfunction in atherosclerosis by inhibiting Hippo signaling to activate YAP.
Answers are grounded in this paper and cite their sources.
Uncovers how JCAD promotes endothelial dysfunction through Hippo signaling, suggesting a mechanistic link to coronary artery disease risk.
Objective- A large number of genetic loci have been associated with risk of coronary artery disease (CAD) through genome-wide association studies, however, for most loci the underlying biological mechanism is unknown. Determining the molecular pathways and cellular processes affected by these loci will provide new insights into CAD pathophysiology and may lead to new therapies. The CAD-associated variants at 10p11.23 fall in JCAD, which encodes an endothelial junction protein, however, its molecular function in endothelial cells is not known. In this study, we characterize the molecular role of JCAD (junctional cadherin 5 associated) in endothelial cells. Approach and Results- We show that JCAD knockdown in endothelial cells affects key phenotypes related to atherosclerosis including proliferation, migration, apoptosis, tube formation, and monocyte binding. We demonstrate that JCAD interacts with LATS2 (large tumor suppressor kinase 2) and negatively regulates Hippo signaling leading to increased activity of YAP (yes-associated protein), the transcriptional effector of the pathway. We also show by double siRNA knockdown that the phenotypes caused by JCAD knockdown require LATS2 and that JCAD is involved in transmission of RhoA-mediated signals into the Hippo pathway. In human tissues, we find that the CAD-associated lead variant, rs2487928, is associated with expression of JCAD in arteries, including atherosclerotic arteries. Gene co-expression analyses across disease-relevant tissues corroborate our phenotypic findings and support the link between JCAD and Hippo signaling. Conclusions- Our results show that JCAD negatively regulates Hippo signaling in endothelial cells and we suggest that JCAD contributes to atherosclerosis by mediating YAP activity and contributing to endothelial dysfunction.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2018) studied Coronary artery disease and atherosclerosis. JCAD knockdown and CAD-associated lead variant rs2487928 was evaluated on Hippo signaling regulation, YAP activity, and atherosclerosis-related endothelial phenotypes. JCAD at the 10p11.23 CAD locus interacts with LATS2 to negatively regulate Hippo signaling, increasing YAP activity and promoting endothelial dysfunction in atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: